JFG Wealth Management LLC Makes New Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

JFG Wealth Management LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 738 shares of the company’s stock, valued at approximately $305,000.

A number of other large investors have also made changes to their positions in IDXX. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories during the third quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth about $31,000. Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $37,000. Finally, Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $38,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Down 0.8 %

Shares of IDXX opened at $459.86 on Wednesday. The company’s 50-day simple moving average is $433.24 and its 200-day simple moving average is $451.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The stock has a market capitalization of $37.66 billion, a PE ratio of 43.10, a P/E/G ratio of 3.41 and a beta of 1.37.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several analyst reports. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America upped their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Finally, Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.